Literature DB >> 27314995

[Duration of treatment and oral administrad on of antibiotics in community acquired pneumonia].

Mónica A Bernal-Vargas, Jorge A Cortés.   

Abstract

Community acquired pneumonia (CAP) is an important cause of morbidity and mortality around the world, with high treatment costs due to hospitalization and complications (adverse events due to medications, antibiotic resistance, healthcare associated infections, etc.). It has been proposed administration of short courses and early switch of intravenous administration to oral therapy to avoid costs and complications. There are recommendations about these topics in national and intemational guidelines, based on clinical trials which do not demónstrate diffe-rences in mortality and complications when there is an early change from intravenous administration to the oral route. There are no statistically significant differences in safety and resolution of the disease when short and long treatment schemes were compared. In this review we present the most important guidelines and clinical studies, taking into account the pharmacological differences between different medications. It is considered that early switch from intravenous to oral administration route and use of short cycles in CAP is safe and brings benefits to patients and institutions.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27314995     DOI: 10.4067/S0716-10182016000200007

Source DB:  PubMed          Journal:  Rev Chilena Infectol        ISSN: 0716-1018            Impact factor:   0.520


  1 in total

Review 1.  Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.

Authors:  Jesús López-Alcalde; Ricardo Rodriguez-Barrientos; Jesús Redondo-Sánchez; Javier Muñoz-Gutiérrez; José María Molero García; Carmen Rodríguez-Fernández; Julio Heras-Mosteiro; Jaime Marin-Cañada; Jose Casanova-Colominas; Amaya Azcoaga-Lorenzo; Virginia Hernandez Santiago; Manuel Gómez-García
Journal:  Cochrane Database Syst Rev       Date:  2018-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.